Roche, Sanofi, Bojian and other pharmaceutical companies announced the latest clinical data of MS drugs

CompilationTom Lee, newborn

Multiple sclerosis (MS) is a disabling disease of the central nervous system that affects more than one million Americans.

Genentech

Genentech released long-term data from OPERA Phase I, OPERA Phase II, and Phase III studies at the meeting.

In addition, data from the Phase III ORATORIOOLE study showed that in patients with primary progression, early treatment with Ocrevus has clinical benefits

The company also released data from a shorter-term infusion study of Ocrevus in minority patients.

Bojian

Boston-based Biogen also shared trial data at the ECTRIMS conference, demonstrating the benefits of its interferon treatment for multiple sclerosis patients who have been vaccinated against COVID-19

Approximately 92% of patients in the research analysis received mRNA vaccines and used immunoglobulin G (IgG) assays to measure immune responses

Bojian Chief Medical Officer Maha Radhakrishnan said that the results of this analysis provide important information for multiple sclerosis patients during the global pandemic of new coronary pneumonia

Sanofi

Sanofi shared data from its experimental multiple sclerosis drug Tolebrutinib, an oral brain permeable Bruton's tyrosine kinase (BTK) inhibitor

In addition, Tolebrutinib is being evaluated in a number of phase III clinical trials, including for the treatment of relapsing multiple sclerosis as well as non-relapsed secondary progressive multiple sclerosis and primary progressive multiple sclerosis

According to Sanofi, this data makes Tolebrutinib the only BTK inhibitor under development for multiple sclerosis, which has been shown to directly regulate microglia

In addition, at the ECTRIMS conference, Bristol-Myers Squibb also announced more data from the long-term DAYBREAK study of Zeposia (once a day, orally) for the treatment of MS

Reference source:

1.

2.